Breakthrough combo fights deadliest TB strains
NCT ID NCT02333799
Summary
This study tested a new combination of three drugs (bedaquiline, pretomanid, and linezolid) to treat the most difficult forms of tuberculosis. It involved 109 people with extensively drug-resistant TB (XDR-TB) or multi-drug resistant TB (MDR-TB) that hadn't responded to other treatments. The goal was to see if a shorter, 6-9 month course of these drugs could safely and effectively control the infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
King DinuZulu Hospital Complex
Sydenham, Durban, 4001, South Africa
-
Sizwe Tropical Disease Hospital
Sandringham, Johannesburg, 2131, South Africa
-
Task Applied Science - Brooklyn Chest Hospital
Ysterplaat, Cape Town, 7405, South Africa
Conditions
Explore the condition pages connected to this study.